Project Grant R01HL180636
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded Seattle Children's Hospital $930,637 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to conduct PROSPER (Pulmonary Recovery and Outcomes After Severe Pediatric Respiratory Illness), a multicenter prospective longitudinal cohort study examining how impaired pulmonary function contributes to physical and health-related quality-of-life morbidity among children surviving acute respiratory failure. The...
- The National Heart, Lung, and Blood Institute awarded Seattle Children's Hospital $1,736,235 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sleep health and its relationship to childhood systemic lupus erythematosus (CSLE) symptoms within the sociocultural and neighborhood contexts of affected youth. The research examines associations between sleep health dimensions—including duration, efficiency, regularity, and daytime sleepiness—and CSLE...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $825,533 for Project Grant R01HL182745 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates glycorna-based control of angiogenesis through heparan sulfate binding growth factors. Research focuses on how vascular endothelial growth factor (VEGF-A) orchestrates vascular and cardiac development by binding...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $781,860 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the novel role of neutrophils in mediating endothelial regeneration and vascular repair in sepsis and acute respiratory distress syndrome (ARDS). The research addresses ARDS pathology, specifically endothelial barrier injury and increased vascular...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $778,202 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research targeting inflammaging-induced endothelial injury and acute respiratory distress syndrome (ARDS) development in aging lungs. The research investigates how aging influences endothelial barrier injury mechanisms in ARDS, with focus on endothelial NADPH oxidase 2 (NOX2)...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $876,614 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite prospective cohort study advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation. The research will enroll 400 children in English and Spanish language families using long-term home mechanical...
- The National Heart, Lung, and Blood Institute (NHLBI) of the Department of Health and Human Services awarded $1,545,864 to the University of Pittsburgh on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund Project Grant R01HL187347, an investigation into immune-mediated lung repair following early life respiratory viral infection. The research defines mechanisms of viral lower respiratory tract infection (LRTI)–driven lung damage and repair in neonates, with...
- The National Heart, Lung, and Blood Institute awarded ST Jude Children's Research Hospital Inc. $150,104 on March 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate influenza-induced lung damage and hypoxemia. The research project, "Decoding Influenza-Induced Damage: What's All the Hyp(oxia) About?," uses damage-responsive fibroblasts (DRFibs) and ADAMTS4-knockout mice to elucidate how preventing T cell and fibroblast communication affects T cell...
The National Heart, Lung, and Blood Institute awarded Seattle Children's Hospital, doing business as Seattle Children's Research Institute, $1,839,440 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how heavy chain hyaluronan and TSG-6 modulate lung inflammation during respiratory syncytial virus (RSV) infection. The research examines the extracellular matrix's role in RSV pathogenesis, focusing on age-dependent inflammation in young children. The project comprises three aims: determining spatial and temporal changes in the hyaluronan matrix driven by TSG-6 and how these changes affect host response to RSV in juvenile versus adult mice; defining the composition and contextual nature of TSG-6-modified, hyaluronan-enriched extracellular matrix during RSV infection using primary ex vivo bronchial epithelial cell and lung fibroblast cocultures derived from young pediatric subjects; and evaluating strategies to block pathologic heavy chain hyaluronan complexes. The work leverages expertise in hyaluronan matrix characterization and ex vivo primary cell coculture models that mimic human lung tissue responses. Performance occurs in Seattle, Washington. The period of performance extends through May 31, 2031. The award is classified as a Project Grant, an assistance type under the NHLBI's competitive research funding mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/21/26 | ||
| Not listed | $919.7k | 8/10/26 |